Skip to main content

Stargardt Disease clinical trials at University of California Health

2 in progress, 1 open to eligible people

Showing trials for
  • ALK-001 on Stargardt Disease

    open to eligible people ages 8-70

    The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD

    at UCLA

  • Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

    Sorry, in progress, not accepting new patients

    To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).

    at UCLA

Our lead scientists for Stargardt Disease research studies include .

Last updated: